Abstract Alzheimer's disease (AD), the most common form of dementia, is characterized by
the accumulation of amyloid β (Aβ) and hyperphosphorylated tau protein aggregates …

Clinicopathologic correlation studies are critically important for the field of Alzheimer disease
(AD) research. Studies on human subjects with autopsy confirmation entail numerous …

Introduction Plasma glial fibrillary acidic protein (GFAP) is a marker of astroglial activation
and astrocytosis. We assessed the ability of plasma GFAP to detect Alzheimer's disease …

The amyloid hypothesis has driven drug development strategies for Alzheimer's disease for
over 20 years. We review why accumulation of amyloid-beta (Aβ) oligomers is generally …

Clinico-pathological correlation studies and positron emission tomography amyloid imaging
studies have shown that some individuals can tolerate substantial amounts of Alzheimer's …

The causative role of amyloid β 1–42 (Aβ42) aggregation in the pathogenesis of Alzheimer's
disease (AD) has been under debate for over 25 years. Primarily, scientific efforts have …

Clarifying the relationships between neuropsychiatric symptoms and Alzheimer's disease
(AD)-related pathology may open avenues for effective treatments. Here, we investigate the …

Alzheimer's disease (AD) is a devastating neurodegenerative disorder and a major medical
problem. Here, we have investigated the impact of amyloid-β (Aβ) oligomers, AD-related …

The identification of amyloid-β precursor protein (APP) pathogenic mutations in familial early
onset Alzheimer's disease (AD), along with knowledge that amyloid-β (Aβ) was the principle …

Sustained microglial activation and increased pro-inflammatory signalling cause chronic
inflammation and neuronal damage in Alzheimer's disease (AD). Resolution of inflammation …